So, you want to invest in AbbVie (NYSE: ABBV) because it's a promising dividend-paying stock, and you also want to receive $1 ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

AbbVie (ABBV) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. At the same time, ...

AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...

Bearish flow noted in AbbVie (ABBV) with 6,427 puts trading, or 1.5x expected. Most active are 4/11 weekly 210 puts and Mar-25 190 calls, with ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Representative Jefferson Shreve (R-Indiana) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on March ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation.

Currently, the stock is trading at $211.54 per share, having risen 19.04% since the beginning of the year. Over the past 12 months, AbbVie returned 16.83% to its investors. In March, AbbVie Inc ...